Carisma Therapeutics Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2024-01-08: Study NCT06254807; Company role Lead sponsor; Phase Phase 1; Status Unknown.
- 2021-02-02: Study NCT04660929; Company role Lead sponsor; Phase Phase 1; Status Unknown.
- 2015-08: Study NCT02449239; Company role Lead sponsor; Phase Phase 3; Status Completed.
- 2007-05: Study NCT00481936; Company role Lead sponsor; Phase Phase 1; Status Terminated.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2024-01-08 | NCT06254807 CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors | Lead sponsor | Phase 1 | Unknown | HER2-positive | 6 | 2026-03-31 |
| 2021-02-02 | NCT04660929 CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | Lead sponsor | Phase 1 | Unknown | HER2-positive; Adenocarcinoma; Bile Duct Cancer; Biliary Tract Cancer; Bladder Cancer; Breast Cancer; Breast Neoplasm; Carcinoma, Ductal; Carcinoma, Hepatocellular; Cancer; Lung Cancer, Non-Small-Cell; Carcinoma, Ovarian Epithelial; Carcinoma, Small Cell; Carcinoma, Squamous; Carcinoma, Transitional Cell; Colorectal Cancer; Esophagogastric Junction Neoplasms; Inflammatory Breast Cancer; Stomach Neoplasms; Malignant Neoplasms; Ovarian Neoplasms; Pancreatic Cancer; HER2-positive Solid Tumors; HER2-positive Breast Cancer; HER2-positive Gastric Cancer; HER-2 Protein Overexpression; HER-2 Gene Amplification; Prostate Cancer; Head and Neck Cancer; Endometrial Cancer; Lung Cancer, Small Cell | 48 | 2024-12-31 |
| 2015-08 | NCT02449239 Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG | Lead sponsor | Phase 3 | Completed Results posted | Bladder Cancer | 133 | 2022-05 |
| 2007-05 | NCT00481936 Study of the Safety of VB6-845 in Patients With Advanced Solid Tumours of Epithelial Origin | Lead sponsor | Phase 1 | Terminated | Neoplasms, Glandular and Epithelial | 15 | 2008-04 |
| 2007-03 | NCT00462488 Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ | Lead sponsor | Phase 2 | Completed Results posted | Urinary Bladder Cancer; Bladder Cancer; Bladder Neoplasms; Bladder Tumors | 46 | 2009-10 |
| 2006-01 | NCT00272181 Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer | Lead sponsor | Phase 2 | Terminated | Squamous Cell Carcinoma of the Head and Neck; Carcinoma, Squamous Cell; Neoplasms, Squamous Cell; Head and Neck Neoplasms; Mouth Neoplasms; Head and Neck Cancer | 15 | 2007-10 |
| 2005-12 | NCT00412776 Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer | Lead sponsor | Phase 2, Phase 3 | Terminated | Carcinoma, Squamous Cell of Head and Neck; Carcinoma, Squamous Cell; Neoplasms, Squamous Cell; Head and Neck Neoplasms; Mouth Neoplasms; Head and Neck Cancer | 165 | 2008-04 |